Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Norton

Showing results (141-150 of 293) with videos related to

Pageof 30
Sort By:
Cell|July 10, 2012
A CXCL1 paracrine network links cancer chemoresistance and metastasisSwarnali Acharyya, Thordur Oskarsson, Sakari Vanharanta, et al.
NPJ Genomic Medicine|November 25, 2021
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitorsRena Elkin, Jung Hun Oh, Ying L Liu, et al.
Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21Teresa A Gilewski, Govind Ragupathi, Maura Dickler, et al.
Genetic Epidemiology|October 6, 2005
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mappingNathan A Ellis, Tomas Kirchhoff, Nandita Mitra, et al.
Plos One|December 16, 2014
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survivalGary Tozbikian, Edi Brogi, Kyuichi Kadota, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
JAMA|March 3, 2005
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancerHyman B Muss, Susan Woolf, Donald Berry, et al.
JAMA Dermatology|March 7, 2019
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy AlopeciaAzael Freites-Martinez, Donald Chan, Vincent Sibaud, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Pageof 30

Showing results (141-150 of 293) with videos related to

Sort By:
Pageof 30
Cell|July 10, 2012
A CXCL1 paracrine network links cancer chemoresistance and metastasisSwarnali Acharyya, Thordur Oskarsson, Sakari Vanharanta, et al.
NPJ Genomic Medicine|November 25, 2021
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitorsRena Elkin, Jung Hun Oh, Ying L Liu, et al.
Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21Teresa A Gilewski, Govind Ragupathi, Maura Dickler, et al.
Genetic Epidemiology|October 6, 2005
Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mappingNathan A Ellis, Tomas Kirchhoff, Nandita Mitra, et al.
Plos One|December 16, 2014
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survivalGary Tozbikian, Edi Brogi, Kyuichi Kadota, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
JAMA|March 3, 2005
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancerHyman B Muss, Susan Woolf, Donald Berry, et al.
JAMA Dermatology|March 7, 2019
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy AlopeciaAzael Freites-Martinez, Donald Chan, Vincent Sibaud, et al.
Clinical Breast Cancer|July 7, 2011
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp, Joseph A Sparano, James Caravelli, et al.
Pageof 30